Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/8006
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BURZYKOWSKI, Tomasz | - |
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | Yothers, Greg | - |
dc.contributor.author | Sakamoto, Junichi | - |
dc.contributor.author | Sargent, Dan | - |
dc.date.accessioned | 2008-03-17T09:15:46Z | - |
dc.date.available | NO_RESTRICTION | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | LIFETIME DATA ANALYSIS, 14(1). p. 54-64 | - |
dc.identifier.issn | 1380-7870 | - |
dc.identifier.uri | http://hdl.handle.net/1942/8006 | - |
dc.description.abstract | Sargent et al (J Clin Oncol 23: 8664-8670, 2005) concluded that 3-year disease-free survival (DFS) can be considered a valid surrogate (replacement) endpoint for 5-year overall survival (OS) in clinical trials of adjuvant chemotherapy for colorectal cancer. We address the question whether the conclusion holds for trials involving other classes of treatments than those considered by Sargent et al. Additionally, we assess if the 3-year cutpoint is an optimal one. To this aim, we investigate whether the results reported by Sargent et al. could have been used to predict treatment effects in three centrally randomized adjuvant colorectal cancer trials performed by the Japanese Foundation for Multidisciplinary Treatment for Cancer (JFMTC) (Sakamoto et al. J Clin Oncol 22:484-492, 2004). Our analysis supports the conclusion of Sargent et al. and shows that using DFS at 2 or 3 years would be the best option for the prediction of OS at 5 years. | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject.other | surrogate endpoint; colorectal cancer; surrogate threshold effect | - |
dc.title | Exploring and validating surrogate endpoints in colorectal cancer | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 64 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 54 | - |
dc.identifier.volume | 14 | - |
local.format.pages | 11 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Hasselt Univ, Ctr Stat, B-3590 Diepenbeek, Belgium. MSOURCE Med Dev, Warsaw, Poland. IDDI, Louvain, Belgium. NSABP, Ctr Biostat, Pittsburgh, PA USA. Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan. Mayo Clin, Coll Med, Rochester, MN USA.Burzykowski, T, Hasselt Univ, Ctr Stat, Agoralaan D, B-3590 Diepenbeek, Belgium.tomasz.burzykowski@uhasselt.be | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.isi | 000252945100008 | - |
dc.identifier.url | http/dx.doi.org/10.1007/s10985-007-9079-4 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.validation | ecoom 2009 | - |
item.contributor | BURZYKOWSKI, Tomasz | - |
item.contributor | BUYSE, Marc | - |
item.contributor | Yothers, Greg | - |
item.contributor | Sakamoto, Junichi | - |
item.contributor | Sargent, Dan | - |
item.fullcitation | BURZYKOWSKI, Tomasz; BUYSE, Marc; Yothers, Greg; Sakamoto, Junichi & Sargent, Dan (2008) Exploring and validating surrogate endpoints in colorectal cancer. In: LIFETIME DATA ANALYSIS, 14(1). p. 54-64. | - |
crisitem.journal.issn | 1380-7870 | - |
crisitem.journal.eissn | 1572-9249 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Exploring and Validating Surrogate Endpoints in Colorectal Cancer.pdf | Peer-reviewed author version | 131 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
27
checked on May 10, 2024
Page view(s)
56
checked on Sep 7, 2022
Download(s)
226
checked on Sep 7, 2022
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.